IL-6 and IL-8 have been shown to cause immunosuppression in the TME [37,38] and regulate tumor progression, metastasis, and invasion [39,40]; in this context, immune-based therapeutic intervention targeting IL-6 and IL-8 may represent a new therapeutic strategy in patients with oral cancer. Here, CXCL8 is linked to neoplasm.